Development Pipeline (as of July 22, 2010)
Development Pipeline [
80KB]
80KB]Oncology
| Development code | Indication * Additional indication |
Stage (date) |
Generic name Product name Dosage form |
Origin Overseas name (Collaborator) |
Mode of Action |
|---|---|---|---|---|---|
| RG435 | Breast cancer * | Filed Oct.09 |
bevacizumab Avastin® Injection |
Roche Avastin® |
Humanized anti-VEGF (Vascular Endothelial Growth Factor) monoclonal antibody |
| Colon cancer (adjuvant) * | Phase III Multinational study |
||||
| Gastric cancer * | Phase III Multinational study |
||||
| Breast cancer (adjuvant) * |
Phase III Multinational study |
||||
| Glioblastoma * | Phase III Multinational study |
||||
| Glioblastoma (relapsed) * | Phase II | ||||
| EPOCH | Chemotherapy-induced anemia * | Filed Nov.09 |
epoetin beta Epogin® Injection |
In-house | Recombinant human erythropoietin |
| RG340 | Gastric cancer * | Filed Mar.10 |
capecitabine Xeloda® Oral |
Roche Xeloda® |
Antimetabolite, 5-FU derivative |
| RG597 | Gastric cancer * | Filed Mar.10 |
trastuzumab Herceptin® Injection |
Roche Herceptin® |
Humanized anti-HER2 monoclonal antibody |
| RG1415 | Pancreatic cancer * | Filed Sep.09 |
erlotinib Tarceva® Oral |
Roche / OSI Tarceva® |
EGFR tyrosine kinase inhibitor |
| Non-small cell lung cancer (1st line) * | Phase II | ||||
| RG1273 | Breast cancer | Phase III Multinational study |
pertuzumab Injection |
Roche | Humanized HER dimerization inhibitory monoclonal antibody |
| MRA | Pancreatic cancer * | Phase I / II | tocilizumab Actemra® Injection |
In-house (Roche) |
Humanized anti-human IL-6 receptor monoclonal antibody |
| TP300 | Gastric cancer, etc | Phase II Overseas |
Injection |
In-house | Topoisomerase I inhibitor |
| CIF (RG7167) |
Solid tumors | Phase I | Oral |
In-house (Roche) |
MEK inhibitor |
| Phase I Overseas |
|||||
| CKI27 (RG7304) |
Solid tumors | Phase I | Oral |
In-house (Roche) |
Raf and MEK dual inhibitor |
| Phase I Overseas |
|||||
| GC33 | Liver cancer | Phase I Overseas | Injection |
In-house | Humanized anti-Glypican-3 monoclonal antibody |
| GA101 (RG7159) |
Non-Hodgkin's lymphoma | Phase I | Injection |
GlycArt | Humanized anti-CD20 monoclonal antibody |
| RG3502 | Breast cancer | Phase I | Injection |
Roche | HER2 antibody-drug conjugate |
Bone and Joint Diseases
| Development code | Indication * Additional indication |
Stage (date) |
Generic name Product name Dosage form |
Origin Overseas name (Collaborator) |
Mode of Action |
|---|---|---|---|---|---|
| ED-71 | Osteoporosis | Filed Oct.09 |
eldecalcitol Oral |
In-house (Taisho Pharmaceutical) |
Active Vitamin D3 derivative |
| MRA | Systemic onset juvenile idiopathic arthritis (sJIA) * | Phase III Overseas |
tocilizumab Actemra® / RoActemra®(EU) Injection |
In-house (Roche) |
Humanized anti-human IL-6 receptor monoclonal antibody |
| Rheumatoid arthritis (new formulation : subcutaneous injection) | Phase III | tocilizumab Actemra® Injection |
|||
| RG1594 | Rheumatoid arthritis | Phase III Multinational study | ocrelizumab Injection |
Roche | Humanized anti-CD20 monoclonal antibody |
| RG484 | Osteoporosis | Phase II / III | ibandronate sodium hydrate Injection |
Roche Boniva® (US) / Bonviva® (EU) (Taisho Pharmaceutical) |
Bisphosphonate |
| Phase II | ibandronate sodium hydrate Oral |
Renal Diseases
| Development code | Indication * Additional indication |
Stage (date) |
Generic name Product name Dosage form |
Origin Overseas name (Collaborator) |
Mode of Action |
|---|---|---|---|---|---|
| RG744 | Renal anemia | Filed Jul.09 |
Injection |
Roche Mircera® |
Continuous erythropoietin receptor activator |
Transplant, Immunology and Infectious Diseases
| Development code | Indication * Additional indication |
Stage (date) |
Generic name Product name Dosage form |
Origin Overseas name (Collaborator) |
Mode of Action |
|---|---|---|---|---|---|
| RG964 | Compensated liver cirrhosis caused by hepatitis C virus * | Phase II / III | ribavirin Copegus® Oral |
Roche Copegus® |
Anti-viral agent, in combination with Pegasys® |
| RG442 | peginterferon alfa-2a Pegasys® Injection |
Roche Pegasys® |
Peginterferon alfa-2a agent (recombinant) | ||
| Chronic hepatitis B * | Phase II / III | ||||
| NA808 | Chronic hepatitis C | Phase I | Injection |
In-house | Serine palmitoyltransferase inhibitor |
| Phase I Overseas | |||||
| NTZ | Chronic hepatitis C | Development suspended |
nitazoxanide Oral |
Romark Laboratories Alinia® |
Thiazolide compound |
Other Diseases
| Development code | Indication * Additional indication |
Stage (date) |
Generic name Product name Dosage form |
Origin Overseas name (Collaborator) |
Mode of Action |
|---|---|---|---|---|---|
| EPOCH | Predeposit of autologous blood transfusion * | Approved Jun.10 |
epoetin beta Epogin® Injection |
In-house | Recombinant human erythropoietin |
| CSG452 (RG7201) |
Type II diabetes | Phase II Multinational study | Oral |
In-house (Roche) |
SGLT2 inhibitor |
| RG1583 (ITM-077) |
Type II diabetes | Phase II | taspoglutide Injection |
Roche / Ipsen (Teijin) |
GLP-1 analogue |
| RG1678 | Schizophrenia | Phase II Multinational study | Oral |
Roche | GLYT1 inhibitor |
| RG1450 | Alzheimer's disease | Phase I | gantenerumab Injection |
Roche / Morphosys | Human anti-amyloid-beta monoclonal antibody |
To view PDF files,
you will need Adobe® Reader® which is available as a free download.
